![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
– Company will current 5 posters discussing REACT and power kidney illness in the course of the ASN Annual Meeting, November 3 – 6, 2022
– Investor and analyst scientific briefing to be hosted in Orlando, FL on November 3, 2022
WINSTON-SALEM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) — ProfessionalKidney Corp. (Nasdaq: PROK) (“ProKidney”), a number one late clinical-stage mobile therapeutics firm centered on power kidney illness (CKD), immediately introduced that the Company will current 5 posters on REACT and CKD on the upcoming American Society of Nephrology’s (ASN) Kidney Week being held November 3-6, 2022, in Orlando, FL.
Details for the poster shows are as follows:
- Prevalence of Chronic Kidney Disease (CKD): Comparison of Real-World Data (RWD) Sources to the USA National Health and Nutrition Examination Survey (NHANES)
Session Title: CKD: Epidemiology, Risk Factors, Prevention – I [PO2201-1]
Session Date, Time: November 3, 2022, from 10:00 AM to 12:00 PM
Poster Board #: TH-PO887
- Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease
Session Title: Genetics, Development, Regeneration [PO0500]
Session Date, Time: November 4, 2022, from 10:00 AM to 12:00 PM
Poster Board #: FR-PO394
- Gender Differences in Chronic Kidney Disease (CKD) Progression: Real-world Data (RWD) Analysis
Session Title: CKD: Epidemiology, Risk Factors, Prevention – II [PO2201-2]
Session Date, Time: November 4, 2022, from 10:00 AM to 12:00 PM
Poster Board #: FR-PO905
- SGLT2i Prescribers amongst Chronic Kidney Disease (CKD) Patients: Trends in Real-World Data (RWD)
Session Title: CKD: Epidemiology, Risk Factors, Prevention – II [PO2201-2]
Session Date, Time: November 4, 2022, from 10:00 AM to 12:00 PM
Poster Board #: FR-PO904 - Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells Bioactivity
Session Title: CKD: Pathobiology – II [PO2203-2]
Session Date, Time: November 5, 2022, from 10:00 AM to 12:00 PM
Poster Board #: SA-PO957
Abstracts will be accessed on-line at https://www.asn-online.org/education/kidneyweek/.
ProfessionalKidney additionally introduced immediately that it’s going to host an investor and analyst scientific briefing, adopted by a reception, the night of November 3, 2022, in Orlando, FL. To register for the occasion, or for extra info, please contact Dr. Glenn Schulman at [email protected]. Following the occasion, a duplicate of the presentation slides will probably be out there on the Company’s web site at https://investors.prokidney.com/news-events/events-and-presentations.
About ProfessionalKidney
ProfessionalKidney, a pioneer within the therapy of CKD by means of improvements in mobile remedy, was based in 2015 after a decade of analysis. ProfessionalKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous mobile remedy with the potential to not solely sluggish and stabilize the development of CKD, however in some instances doubtlessly drive significant enchancment in kidney perform. Late-stage CKD sufferers, Stage 3b – 4, is a key goal inhabitants for REACT remedy. REACT has acquired Regenerative Medicine Advanced Therapy (RMAT) designation, in addition to FDA and EMA steering, supporting its ongoing Phase 3 medical program that launched in January 2022. For extra info, go to www.prokidney.com.
About CKD
There aren’t any therapies that successfully reverse late-stage CKD. CKD is a severe prognosis with important morbidity and mortality. Notably, the 5-year mortality of newly identified Stage 4 CKD is larger than that of newly identified non-metastatic most cancers. CKD most frequently presents as a progressive decline in kidney perform, in the end ensuing within the failure of the kidneys and the necessity for renal alternative remedy, akin to hemodialysis or kidney transplant. One in three Americans is in danger for CKD which presently impacts roughly 75 million individuals within the United States and Europe and over 400 million throughout Asia. CKD is among the many largest single bills incurred by the U.S. well being care system.
Forward-Looking Statements
This press launch consists of “forward-looking statements” throughout the which means of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProfessionalKidney’s precise outcomes could differ from its expectations, estimates and projections and consequently, you shouldn’t depend on these forward-looking statements as predictions of future occasions. Words akin to “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and comparable expressions (or the detrimental variations of such phrases or expressions) are supposed to establish such forward-looking statements. These forward-looking statements embody, with out limitation, the mixed firm’s expectations with respect to monetary outcomes, future efficiency, growth and commercialization of merchandise, if accepted, the potential advantages and affect of the mixed firm’s merchandise, if accepted, potential regulatory approvals, anticipated monetary impacts and different results of the business mixture on the mixed firm’s business, and the scale and potential development of present or future markets for the mixed firm’s merchandise, if accepted. Most of those components are exterior of the mixed firm’s management and are tough to foretell. Factors which will trigger such variations embody, however should not restricted to: the lack to keep up the itemizing of the mixed firm’s Class A atypical shares on the Nasdaq following the business mixture; the lack to implement business plans, forecasts, and different expectations and to acknowledge the anticipated advantages of the business mixture or establish and notice extra alternatives, which can be affected by, amongst different issues, competitors and the power of the mixed firm to develop and handle development profitably and retain its key staff; the danger of downturns and a altering regulatory panorama within the extremely aggressive biotechnology trade; the lack of the mixed firm to lift financing sooner or later; the lack of the mixed firm to acquire and keep regulatory clearance or approval for its merchandise, and any associated restrictions and limitations of any cleared or accepted product; the lack of the mixed firm to establish, in-license or purchase extra expertise; the lack of mixed firm to compete with different corporations presently advertising or engaged within the biologics market and within the space of therapy of kidney illnesses; the scale and development potential of the markets for the mixed firm’s merchandise, if accepted, and its potential to serve these markets, both alone or in partnership with others; the mixed firm’s estimates concerning bills, future income, capital necessities and desires for extra financing; the mixed firm’s monetary efficiency; the mixed firm’s mental property rights; uncertainties inherent in cell remedy analysis and growth, together with the precise time it takes to provoke and full medical research and the timing and content material of selections made by regulatory authorities; the affect of COVID-19 or geo-political battle such because the battle in Ukraine on the mixed firm’s business; and different dangers and uncertainties indicated every now and then within the proxy assertion referring to the business mixture, together with these underneath “Risk Factors” therein, and within the mixed firm’s different filings with the Securities and Exchange Commission. The mixed firm cautions readers that the foregoing checklist of things isn’t unique and cautions readers to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. The mixed firm doesn’t undertake or settle for any obligation or endeavor to launch publicly any updates or revisions to any forward-looking statements to mirror any change in its expectations or any change in occasions, situations or circumstances on which any such assertion relies.
Contact Information
Investors & Media
Glenn Schulman, PharmD, MPH
SVP, Investor Relations
[email protected]
![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-100x70.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
